Siddha management for Kalanjaga padai (Psoriasis) in children

Clinical Evaluation of Elathy Chooranam (internal) and Narseeraga Thylam for the management of Kalanjaga padai (Psoriasis) in Children

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020198

Enrollment

Registered

2019-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

Intervention1: Elathy Chooranam Narseeraga thylam: Elathy chooranam is a polyherbal formulation 500 to 750 mg Bd to 5 to 12 years children for 45 days Narseeraga thylam is a polyherbal formulation f

Eligibility

Inclusion criteria

Inclusion criteria: children with Erythema, Scaling, Thickness, Itching, Positive Auspitz sign, Candle grease sign

Exclusion criteria

Exclusion criteria: Eczema Psoriatic arthritis Fungal infection Lesions with secondary infection Systemic involvement

Design outcomes

Primary

Measure	Time frame
Efficacy of the trial drug is measured by PASI SCORE and improvement in the clinical condition is assured by reducing the Degrees of involvement of the body region from 5 to 1.Timepoint: 45 days	—

Secondary

Measure	Time frame
Reduction in the remission of the disease and improvement in the quality of life in children.Timepoint: 45 days	—

Countries

India

Contacts

Public ContactDr M Supritha Muthu

National Institute of Siddha

gvennils@gmail.com9789093986

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026